These compounds take a different approach to weight loss than existing medications, which can cause nausea, vomiting and ...

The role of the Gastrointestinal Drugs Advisory Committee (GIDAC) is to review and evaluate available data ‘concerning the safety and effectiveness of marketed and investigational human drug ...

Unfortunately, we also found that GLP-1 drugs come with significant side effects and increase the risk of 19 health conditions we studied, such as gastrointestinal issues, kidney stones, and acute ...

A year after its $175 million IPO in 2024, Arrivent Biopharma Inc. picked up rights to develop and commercialize Lepu Biopharma Co. Ltd.’s antibody-drug conjugate (ADC) candidate, MRG-007, worldwide ...

GI Innovation's next-generation immuno-oncology drug candidate GI-102 has been designated as a 'rare drug in development stage.' The company noted on the 16th that the Ministry of Food and Drug ...

However, they also found that GLP-1 drugs may lead to gastrointestinal, kidney, and pancreas issues. The researchers recommend that doctors closely monitor their patients as these medications ...

Gastrointestinal adverse events partially mediated the weight loss effects among patients with obesity who received tirzepatide vs placebo.